Related Experiment Video
Updated: Dec 12, 2025
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Associated Targets of the Antioxidant Cardioprotection of Ganoderma lucidum in Diabetic Cardiomyopathy by Using Open
Fahmi Shaher1, Hongbin Qiu1, Shuqiu Wang1
1Department of Pathophysiology, College of Basic Medicine, Jiamusi University, Jiamusi, China.
Insights
Diabetic cardiomyopathy (DCM) poses a growing threat. This study identifies the mammalian target of rapamycin (mTOR) as a key target in DCM, suggesting Ganoderma lucidum
Area of Science:
- Cardiovascular Research
- Pharmacology
- Molecular Biology
Background:
- Diabetic cardiomyopathy (DCM) presents a significant clinical challenge with increasing morbidity and mortality despite advances in cardiovascular therapy.
- A pressing need exists for novel and effective therapeutic strategies to combat DCM.
Purpose of the Study:
- To conduct a systematic literature review to identify cellular targets in DCM.
- To investigate the potential cardioprotective role of Ganoderma lucidum (G. lucidum) via its antioxidant effects.
- To utilize the Open Targets Platform (OTP) for identifying therapeutic targets and interventions for DCM.
Main Methods:
- Systematic literature review using the Open Targets Platform (OTP) website (version 19.11).
- Identification of studies linking G. lucidum to DCM and its associated molecular pathways.
- Analysis of PubMed articles on G. lucidum focusing on antioxidant effects and oxidative stress signaling pathways.
Main Results:
- The mammalian target of rapamycin (mTOR) was identified as a shared cell target in DCM across multiple data sources (evidence, drug, text mining) with a notable association score.
- mTOR exhibited the highest association score with autophagy in the context of DCM.
- Out of 1731 PubMed articles on G. lucidum, 33 were selected for their focus on antioxidant effects and molecular pathways related to oxidative stress.
Conclusions:
- mTOR is a validated therapeutic target for DCM.
- The antioxidative properties of G. lucidum can inhibit mTOR.
- G. lucidum offers potential cardioprotection by directly scavenging free radicals and indirectly modulating key signaling pathways including Wnt, Erk1/2, and NF-κB.
Abstract:
Even with substantial advances in cardiovascular therapy, the morbidity and mortality rates of diabetic cardiomyopathy (DCM) continually increase. Hence, a feasible therapeutic approach is urgently needed. Objectives. This work is aimed at systemically reviewing literature and addressing cell targets in DCM through the possible cardioprotection of G. lucidum through its antioxidant effects by using the Open Targets Platform (OTP) website. Methods. The OTP website version of 19.11 was accessed in December 2019 to identify the studies in DCM involving G. lucidum. Results. Among the 157 cell targets associated with DCM, the mammalian target of rapamycin (mTOR) was shared by all evidence, drug, and text mining data with 0.08 score association. mTOR also had the highest score association 0.1 with autophagy in DCM. Among the 1731 studies of indexed PubMed articles on G. lucidum published between 1985 and 2019, 33 addressed the antioxidant effects of G. lucidum and its molecular signal pathways involving oxidative stress and therefore were included in the current work. Conclusion. mTOR is one of the targets by DCM and can be inhibited by the antioxidative properties of G. lucidum directly via scavenging radicals and indirectly via modulating mTOR signal pathways such as Wnt signaling pathway, Erk1/2 signaling, and NF-κB pathways.
